Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2350 • ACR Convergence 2024
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Mikkel Ostergaard³, Bente Glintborg⁴, Signe Møller-Bisgaard⁵, Marion Pons⁶, Jette Heberg⁷, Sara Nysom Christiansen⁸, Simon Horskjær Rasmussen⁶, Anne Gitte Loft⁹, Isabel Castrejon¹⁰, Lucia Otero-Varela¹¹, Jakub Závada¹², Karel Pavelka¹², Jarno Rutanen¹³, Laura Kuusalo¹⁴, Michael Nissen¹⁵, Ziga Rotar¹⁶, Katja Perdan-Pikmajer¹⁶, Miguel Bernardes¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Irene E. van der Horst-Bruinsma¹⁹, Karin Laas²⁰, Brigitte Michelsen²¹, Catalin Codreanu²², Daniela DiGuiseppe²³, Burkhard Moeller²⁴, Gökçe Kenar²⁵, Merete Hetland²⁶ and Lykke Oernbjerg², ¹Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁵Rigshospitalet, Glostrup and Slagelse Hospital, Glostrup, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Rigshospitalet Glostrup, København V, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ⁹Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹Spanish Society of Rheumatology, Madrid, Spain, ¹²Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹³Tampere University Hospital, Tampere, Finland, ¹⁴University of Turku and Turku University Hospital, Turku, Finland, ¹⁵Geneva University Hospital, Geneva, Switzerland, ¹⁶University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁷São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰East-Tallinn Central Hospital, Tallinn, Estonia, ²¹Rigshospitalet, Glostrup and Diakonhjemmet Hospital and Sørlandet Hospital, Kristiansand, Norway, ²²University of Medicine and Pharmacy, Bucharest, Romania, ²³Karolinska Institutet, Stockholm, ²⁴Inselspital - University Hospital Bern, Bern, Switzerland, ²⁵Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…
Abstract Number: 2583 • ACR Convergence 2024
Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
Mikkel Ostergaard¹, Walter Maksymowych², Robert Lambert², Mikael Boesen³, Guillermo J. Valenzuela⁴, Michael R. Bubb⁵, Olga Kubassova⁶, Xenofon Baraliakos⁷, Carlo Selmi⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou¹¹ and Philip Mease¹², ¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²University of Alberta, Edmonton, AB, Canada, ³Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁴Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁵University of Florida, Gainesville, FL, ⁶Image Analysis Group, Philadelphia, PA, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁸Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ⁹Amgen, Halton Hills, ON, Canada, ¹⁰Amgen, Lexington, KY, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase-4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA). Although…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Suzanne D. Khalili¹, Daniel Aletaha³ and Josef Smolen⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, Mitsumasa Kishimoto⁴, Ennio Lubrano⁵, Proton Rahman⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Enrique R. Soriano¹¹, Ruben Queiro Silva¹², Frank Behrens¹³ and Stefan Siebert¹⁴, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁵Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁶Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹³University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…
Abstract Number: 1711 • ACR Convergence 2024
Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Sreemoyee Ghosh¹, Chiara Pastrello², Omar F. Cruz-Correa³, Darshini Ganatra⁴, Katerina Oikonomopoulou³, Melanie Anderson⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Institute of Medical Science, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis (Pso) is a chronic immune mediated inflammatory skin disease. Up to 24% of Pso patients develop psoriatic arthritis (PsA). Pathophysiology of PsA is…
Abstract Number: 2313 • ACR Convergence 2024
Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
Christine Loftis¹, Liron Caplan², Joanna Padilla Zepeda³, Nicole Mukooba³, Mayan Caplan³, Meika Fang⁴, Liya Stolyar⁵, Jessica Walsh⁶, Gail Kerr⁷, Siba Raychaudhuri⁸, Andreas Reimold⁹ and Maida Wong¹⁰, ¹University of Colorado Anschutz School of Medicine, Aurora, CO, ²Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ³University of Colorado, Aurora, CO, ⁴Veterans Affairs, Los Angeles, ⁵Veterans Affairs, Palo Alto, ⁶Veterans Affairs, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Veterans Affairs, Sacramento, ⁹University of Texas Southwestern Medical School, Dallas, ¹⁰Veterans Affairs, Long Beach
Background/Purpose: Studies have suggested a delay between symptom onset and diagnosis for Psoriatic Arthritis (PsA) and axial spondyloarthritis (axSpA). Factors that influence this delay have…
Abstract Number: 2330 • ACR Convergence 2024
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
Rebecca haberman¹, Seungha Um², Catherine Howe³, Kyra Chen², Brianna Fu², Adamary Felipe², Stephanie Eichman², Margaret Coyle⁴, Eileen Lydon⁵, Andrea Neimann², Soumya Reddy⁶, Samrachana Adhikari² and Jose Scher⁷, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, NYC, ³New York University Langone Medical Center, New York, NY, ⁴NYU Langone, Brooklyn, NY, ⁵NYU, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in therapeutics over the past two decades, psoriatic arthritis (PsA) remains difficult to treat, with joint outcomes lagging far behind those…
Abstract Number: 2351 • ACR Convergence 2024
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Irene E. van der Horst-Bruinsma¹, Matthew A. Brown², Floris van Gaalen³, Nigil Haroon⁴, Lianne S Gensler⁵, Alexander Marten⁶, Myriam Manente⁷, George Stojan⁸, Thomas Vaux⁹, Katy White⁹, Atul Deodhar¹⁰ and Martin Rudwaleit¹¹, ¹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Genomics England, London, United Kingdom, ³LUMC, Leiden, Zuid-Holland, Netherlands, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Braine-l'Alleud, Belgium, ⁸UCB Pharma, Atlanta, GA, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (‘uveitis’) is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA), and incidence varies with SpA type and disease duration.1,2,3…
Abstract Number: 2584 • ACR Convergence 2024
Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Philip Mease¹, Alan Kivitz², Elena Muensterman³, Apinya Lertratanakul⁴, Ting Hong⁴, Jingjing Chen⁴, Ejim Mark⁵ and Xenofon Baraliakos⁶, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Takeda Development Center Americas, Cambridge, MA, ⁴Takeda Development Center Americas, Inc., Cambridge, MA, ⁵Takeda Development Center Americas Inc., Cambridge, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase…
Abstract Number: 0224 • ACR Convergence 2024
How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries
Anna EF Hadsbjerg¹, Simon Krabbe², Nora Vladimirova², Adrian Ciurea³, Kristyna Bubova⁴, Monika Gregová⁴, Michael Nissen⁵, Burkhard Moeller⁶, Raphael Micheroli⁷, Susanne Pedersen⁸, Jakub Zavada⁴, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert Lambert¹⁶, Manouk de hOoge¹⁷, Helena V G Elmo¹, Merete Hetland¹⁸, Lykke Oernbjerg¹⁹ and Mikkel Ostergaard²⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, ³University Hospital Zurich, Zürich, Switzerland, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁵Geneva University Hospital, Geneva, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷University Hospital Zurich, Zurich, Switzerland, ⁸Rigshospitalet, København, Denmark, ⁹Institute of Radiology, UMC Ljubljana, Ljubljana, Slovenia, ¹⁰Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, ¹⁵Charite Universitatsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ¹⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹⁹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: MRI of the sacroiliac joints (SIJs) is widely used for diagnosing and monitoring patients with spondyloarthritis (SpA). However, local radiologists might be less familiar with…
Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 0851 • ACR Convergence 2024
Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Lihi Eder¹, Ricardo Acayaba de Toledo², Fahmeen Afgani³, Catherine Bakewell⁴, Philippe Carron⁵, Basant Elnady⁶, Amir Haddad⁷, Arthur Kavanaugh⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, NZEUSSEU TOUKAP Adrien¹², Marcos Rosemffet¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Ágnes Sarolta Szentpétery¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Ilaria Tinazzi¹⁹, Janeth Yinh¹⁰, Gurjit Kaeley²⁰ and Sibel Aydin²¹, ¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ²FAMERP, São José do Rio Preto, Brazil, ³Women's College Hospital, Toronto, Canada, ⁴Intermountain Health Care, Salt Lake City, UT, ⁵UZ Gent, Gent, Belgium, ⁶Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ⁷Carmel Medical Centre, Haifa, Israel, ⁸University of California San Diego, La Jolla, CA, ⁹GRAPPA - Patient Research Partner, Haifa, Israel, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Hospital Italiano de Buenos Aires, buenos aires, Argentina, ¹²Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ¹³Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁴Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, FL, ¹⁶Uppsala University Hospital, Uppsala, Sweden, ¹⁷University of California, San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²⁰UF COM-J, Ponte Vedra Beach, FL, ²¹University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…

« Previous Page
1
…
3
4
5
6
7
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].